Paclitaxel as Albumin-Bound Nanoparticles with Gemcitabine for Untreated Metastatic Pancreatic Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
暂无分享,去创建一个
M. Richardson | A. Bagust | J. Greenhalgh | A. Boland | S. Beale | Eleanor Kotas | Rui Duarte | Angela Stainthorpe | Lindsay Banks | Daniel Palmer | Rui V Duarte
[1] L. Curtis,et al. Unit Costs of Health and Social Care 2016 , 2015 .
[2] Chung-Pin Li,et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial , 2015, Oncotarget.
[3] W. Scheithauer,et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. , 2015, Journal of the National Cancer Institute.
[4] K. Chalkidou. About the National Institute for Health and Care Excellence - NICE. , 2013, Acta medica portuguesa.
[5] David Goldstein,et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.
[6] Chung-Pin Li,et al. A randomized controlled trial of gemcitabine plus cisplatin versus gemcitabine alone in the treatment of metastatic pancreatic cancer , 2013, Cancer Chemotherapy and Pharmacology.
[7] E. Basch,et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). , 2012, Journal of pain and symptom management.
[8] Pierre Michel,et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.
[9] R. Goldberg,et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] M. Stauch,et al. Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] H. Einsele,et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Labianca,et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Thompson. British National Formulary (BNF) , 2005 .
[14] W. Miller,et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] D. Walsh,et al. Symptoms of pancreatic cancer. , 1991, Journal of pain and symptom management.
[16] D. Quinton,et al. Unit Costs of Health and Social Care 2004 , 2004 .
[17] W. Scheithauer,et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] J. Higginson. International Agency for Research on Cancer. , 1968, WHO chronicle.